Acne Vulgaris Therapeutics Pipeline Has Moved Towards the Development of Biologicals and Peptides

December 20 18:45 2017

Acne Vulgaris Therapeutics Pipeline Analysis
Acne vulgaris currently exhibits a growing pipeline with approximately 49 drug candidates. According to P&S Market Research.

Various drug candidates have shown positive clinical results and are proceeding towards further development. For instance, In May 2017, Foamix Ltd. announced that FMX101 was generally safe and well tolerated with no drug-related serious adverse events from two double-blind, randomized, placebo-controlled Phase III trials for the treatment of moderate-to-severe acne vulgaris. AndroScience Corporation announced that ASC-J9 in a cream formulation demonstrated a therapeutic effect in lowering lesion counts in moderate to severe acne.

According to the research findings, the drug candidates in acne vulgaris pipeline have move from small molecule towards biologics and peptides. Allergan plc is in the process of manufacturing ANT-1207, also known as botulinum toxin A topical, under the Phase II stage of development for the treatment of acne vulgaris. The therapeutic candidate is an anticholinergic agent, being developed to be administered by topical route. Helix Biomedix, Inc. in a process of developing peptide based molecule, which is in the unknown stage for the treatment of acne vulgaris.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/acne-vulgaris-therapeutics-pipeline-analysis/report-sample

Most of the companies possess advanced technologies for the development of acne vulgaris. For instance, Sol-Gel Technologies Ltd. introduced a technology known as “sol-gel”, in which silica on site forms a microcapsule shells and release drugs at site of action. The drug substance that is added during the sol-gel reaction is encapsulated, through which a core-shell structure is formed. Therefore, the contribution of advanced technologies for making targeted therapies is a key factor driving the growth of acne vulgaris pipeline therapeutics.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acne-vulgaris-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of acne vulgaris therapeutics pipeline include Sol-Gel Technologies Ltd., Realm Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., and Promius Pharma, LLC (subsidiary of Dr. Reddy’s Laboratories Ltd.).

Acne Vulgaris Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

About P&S Market Research

P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.

With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication.  Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Media Contact
Company Name: P&S Market Research
Contact Person: Kundan
Email: Send Email
Phone: +1-888-778-7886
Address:347 5th Ave. #1402- 210
City: New York City
State: New York
Country: United States
Website: https://www.psmarketresearch.com/market-analysis/acne-vulgaris-therapeutics-pipeline-analysis

  Categories: